Mahmoud Hager A, Botros Shahira Ka, Fouad Abdelhamid Mohamed, Kamel Mahmoud M, Abdel Aziz Rania S
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Clinical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Clin Med Insights Oncol. 2024 Nov 3;18:11795549241295649. doi: 10.1177/11795549241295649. eCollection 2024.
Acute myeloid leukemia (AML) has a heterogeneous molecular profile, clinical presentations, and response to treatments and outcomes. DNA methylation is conducted by DNA methyltransferases including DNMT3B. Poly ADP-ribose polymerase 1 belongs to a family of enzymes that mediate important cellular processes including DNA repair, transcription, and cell death/cell proliferation, and it is involved in the development, spread, treatment, and prognosis of some cancers. The objective of this study is to assess the impact of and genes expression on laboratory characteristics, response to treatment and survival in Egyptian cytogenetically normal AML patients.
This study included 67 Egyptian CN-AML patients in addition to 8 healthy bone marrow donors. Measurement of and gene expression was done on bone marrow samples via real-time semiquantitative polymerase chain reaction.
Expression of both and genes was significantly upregulated in AML ( = .001, = .036, respectively). Upregulated was associated with higher total leukocyte count (TLC), PB, and BM blast cell%. Also, upregulated correlated with higher TLC, PB, and BM blast cell%. High expression of both and correlated with greater frequencies of . High expression, and combined upregulation of both and genes associated significantly with ELN stratification. But no correlation was found with response (CR), overall survival (OS), disease-free survival (DFS), or event-free survival (EFS).
Our findings highlight the importance of considering and expression levels as potential prognostic biomarkers for progression and aggressiveness of CN-AML patients in AML. Assessing their expression levels could be an indicator to guide treatment decisions and potentially improve patient outcomes.
急性髓系白血病(AML)具有异质性的分子特征、临床表现以及对治疗的反应和预后。DNA甲基化由包括DNMT3B在内的DNA甲基转移酶进行。聚ADP - 核糖聚合酶1属于一类介导重要细胞过程(包括DNA修复、转录以及细胞死亡/细胞增殖)的酶家族,并且它参与某些癌症的发生、扩散、治疗和预后。本研究的目的是评估 和 基因表达对埃及细胞遗传学正常的AML患者的实验室特征、治疗反应和生存的影响。
本研究纳入了67例埃及细胞遗传学正常的AML患者以及8名健康骨髓供者。通过实时半定量聚合酶链反应对骨髓样本进行 和 基因表达的检测。
AML中 和 基因的表达均显著上调(分别为 = 0.001, = 0.036)。 上调与更高的总白细胞计数(TLC)、外周血(PB)和骨髓原始细胞百分比相关。同样, 上调与更高的TLC、PB和骨髓原始细胞百分比相关。 和 的高表达与 的更高频率相关。 高表达以及 和 基因的联合上调与欧洲白血病网络(ELN)分层显著相关。但未发现与缓解(CR)、总生存(OS)、无病生存(DFS)或无事件生存(EFS)相关。
我们的研究结果强调了将 和 表达水平作为细胞遗传学正常的AML患者在AML中的进展和侵袭性的潜在预后生物标志物的重要性。评估它们的表达水平可能是指导治疗决策并潜在改善患者预后的一个指标。